Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.
Use of ezetimibe to manage elevated low-density lipoprotein cholesterol (LDL-C) levels in individuals aged ≥75 years proves beneficial in the primary prevention of coronary artery disease (CAD) events, reducing the risk of a composite of sudden cardiac death, myocardial infarction, coronary revascularization or stroke, according to data from the open-label EWTOPIA* 75 trial.
The three-drug combination of telmisartan, amlodipine and rosuvastatin yields significant reductions in blood pressure and low-density lipoprotein cholesterol levels in patients with hypertension and dyslipidaemia while having a good safety profile and tolerability, according to data from the J-TAROS* trial.
A dietary strategy of carbohydrate restriction proves superior to low-fat diets in terms of improving lipid markers in individuals with cardiometabolic risk, owing to its strong effects on high-density lipoprotein cholesterol and triglycerides, according to a meta-analysis.
Young, healthy individuals at low risk for atherosclerotic cardiovascular disease (ASCVD) events may still face a heightened lifetime risk of death from CV events if they have elevated LDL-C levels of ≥160 mg/dL, reveals the CCLS*.
Lipid-lowering with ezetimibe monotherapy was effective for the primary prevention of atherosclerotic cardiovascular (CV) events in middle- to high-risk elderly Japanese patients with hypercholesterolaemia, according to the EWTOPIA75* study presented at AHA 2018 Scientific Sessions.
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
Not only does treatment with the PCSK9* inhibitor alirocumab reduces cardiovascular (CV) events along with plunges in LDL-C levels, it was also associated with a reduced risk of all-cause mortality compared with placebo in patient with a recent acute coronary syndrome (ACS) and persistently high cholesterol despite maximal statin therapy, according to top-line results from the ODYSSEY** Outcomes trial.
There appear to be several patients with psoriasis and psoriatic arthritis (PsA) who are underdiagnosed and undertreated for hypertension and dyslipidaemia in actual situations, a recent study has found.